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ABSTRACT
Residual tumor resulting in tumor recurrence after various anticancer therapies 
is an unmet challenge in current clinical oncology. This study aimed to investigate 
the hypothesis that radioiodinated hypericin (131I-Hyp) may inhibit residual tumor 
recurrence after microwave ablation (MWA) on rat orthotopic liver allograft sarcoma 
models.
Thirty Sprague-Dawley (SD) rats with hepatic tumors were divided into three 
groups: Group A received laparotomy MWA and sequential intravenous injection 
(i.v.) of 131I labelled hypericin (131I-Hyp) in a time interval of 24 h; Group B received 
only laparotomy MWA; Group C was a blank control. Tumor inhibitory effects were 
monitored with in vivo magnetic resonance imaging (MRI) and these findings were 
compared to histopathology data before (baseline, day 0) and 1, 4, and 8 days after 
MWA. In addition, biodistribution of 131I-Hyp was assessed with in vivo single-photon 
emission computed tomography-computed tomography (SPECT-CT) imaging, in vitro 
autoradiography, fluorescent microscopy, and gamma counting.
A fast clearance of 131I-Hyp and increasing deposit in necrotic tumors appeared 
over time, with a significantly higher radioactivity than other organs (0.9169 ± 1.1138 
% ID/g, P < 0.01) on day 9. Tumor growth was significantly slowed down in group 
A compared to group B and C according to MRI images and corresponding tumor 
doubling time (12.13 ± 1.99, 4.09 ± 0.97, 3.36 ± 0.72 days respectively). The crescent 
tagerability of 131I-Hyp to necrosis was visualized consistently by autoradiography 
and fluorescence microscopy.
In conclusion, 131I-Hyp induced necrosis targeted radiotherapy improved 
therapeutic outcomes of MWA on rat orthotopic liver allograft sarcoma models.
INTRODUCTION
Liver cancer treatment has advanced significantly 
[1-3]. Locoregional thermal ablations have evolved as 
crucial complementarily therapies [4-9] for liver cancer, 
and among these strategies, percutaneous microwave 
ablation (MWA) with real-time ultrasonographic 
guidance is favored because it is minimally invasive 
with fewer complications, and offers accurate targeting 
with substantially long-term curative effects compared to 
surgical resection [5, 10, 11]. Even with these superiorities, 
local or distant tumor metastases are identified after 
treatment, often due to large tumors volume and tumors 
that are adjacent to large vessels and/or vital organs which 
are continual challenges in efforts to completely eradicate 
disease. Reports regarding to the targeted treatment of 
residual tumors are also scarce.
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Epstein’s group [12] initially reported that injection 
of radioiodinated monoclonal antibody could target intra-
cellular antigens exposed in necrotic and degenerating 
malignant tumor regions and that this internal irradiation 
could exploit antigen-antibody binding. 131I-chTNT 
(iodinated chimeric tumor necrosis therapy monoclonal 
antibody) has been applied to treat advanced lung cancer 
in China. However, clinical application of 131I-chTNT is 
limited by the macromolecule immunogenicity and bone 
marrow suppression.
Recently, Yun’s group [13] used brachytherapy 
in mice bearing subcutaneous S180 tumors. With 
radioiodinated sennidin A (131I-SA), the authors targeted 
necrosis induced by injection of the vascular disrupting 
agent (VDA), combretastatin A4 phosphate (CA4P, i.v.), 
and noted tumoricidal effects and increased median 
survival in animals. However, that study was partly limited 
by the non-clinical availability of CA4P. In addition, the 
microenvironment of internal organs differed greatly from 
subcutaneous microenvironment for tumor growth.
Hypericin, a naturally occurring small molecule 
extracted from Hypericum perforatum [14], has been 
studied as a photosensitizer for photodynamic therapy 
[15]. Recently, hypericin has been afresh recognized 
due to its exceptional affinity for necrotic tissue [16-19]. 
Compared with some targeted drugs that just anchor to 
viable tumor tissues, hypericin could specifically and 
steadily bind to the tumor necrotic tissue with high 
target-to-nontarget ratios [16-19]. 131I-Hyp has also been 
identified as a potential therapeutic radiopharmaceutical 
in the field of so-called necrosis target radiotherapy 
compared with other previously identified specific agents 
[18, 19].
Furthermore, rather than hitting viable cancer cells 
undergoing numerous mutations that cause uncontrollable 
growth and escape from annihilation, targeting necrotic 
cells hold following three superiorities at least: (1) stable 
target with less heterogeneity; (2) generic target that 
widely exists in solid tumors; (3) superior specificity due 
to the exchange of macromolecules between intracellular 
and extracellular environment. Moreover, encouraging 
results have been published regarding the combination 
of VDA or thermal ablation with 131I-Hyp to treat 
subcutaneous solid tumors [13, 20, 21].
Based on the above considerations, we hypothesized 
that 131I-Hyp could specifically bind to the necrotic 
liver tumor induced by MWA and further irradiate the 
surrounding residual viable tumor with persistent cross-
fire beta particles. To examine this, we established 
necrosis target spot by MVA, following intravenous 
injection of therapeutic nuclide 131I labeled hypericin 
(131I-Hyp) on rat orthotopic liver allograft sarcoma model. 
The targetability of 131I-Hyp was evaluated by SPECT-
CT images, autoradiography, fluorescent microscopy and 
gamma counting. Tumor growth was dynamic monitoring 
by in vivo MRI and corresponding histopathology.
RESULTS
Animal models
Rat orthotopic liver allograft sarcoma models 
were successfully established and residual tumors were 
induced with MWA (Figure 2A) as evidenced by contrast 
enhanced MRI (Figure 2D, 2E) and eventually post-
mortem histopathology data (Figure 2F, 2G). All animals 
survived surgeries, tumor growth and in vivo imaging 
processes and only one animal died 2 days after the second 
laparotomy, probably due to severe abdominal distension 
and subsequent shock.
Radiolabeling and in vitro stability studies
131I-Hyp labeling exceeded 90% according to 
ascending paper chromatography. 131I-Hyp was intact after 
72 h by incubated in rat serum with radiochemical purity 
over 90%, which suggested a favorable stability.
Biodistribution
The biodistribution results were shown in Table 1. 
The lungs, large intestines, viable and necrotic tumors 
were radioactive compared to other organs on day 5 
(Figure 3C). At last, increasing radioactivity in necrotic 
tumors on day 9 was significantly higher than that of other 
organs (0.9169 ± 1.1138, P < 0.01) (Figure 3D).
SPECT-CT imaging
On day 3, both axial and coronal fusion images 
depicted high radioactive nuclide concentration (“hot 
spots”) on left liver lobes at the tumor site. However, the 
signal was also very hyperintense in lung and intestinal 
canal (Figure 3A). Over time, radioactive intensity 
gradually weakened in hepatic lobes and increased in 
thyroids and intestinal canals especially in large intestines 
on day 8 (Figure 3B).
MR imaging
At baseline (day 0), tumor volume appeared no 
significant statistical differences among three groups 
(211.1306 ± 40.0088, 188.2213 ± 50.0269, 169.8402 
± 16.3967 mm3; p>0.05). 24 hours after MVA, tumors 
showed obvious ring-enhancement in group A and B 
(Figure 4A, a2, b2), with a gradually increasing trend 
for group B. Over time, tumor in group A grew virtually 
slower than that of group B and C, which was certified 
by significantly prolonged tumor doubling time (A vs. B, 
12.13 ± 1.99 vs 4.09 ± 0.97 days, p<0.01; A vs. C, 12.13 
± 1.99 vs 3.36 ± 0.72 days, p<0.01) and the eventually 
tumor volumes of three groups were 366.7713 ± 61.7467, 
922.4149 ± 191.9072 and 1346.584 ± 630.6869 mm3 
respectively. However, tumor doubling time showed no 
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significant statistical difference between group B and C 
(4.09 ± 0.97 vs. 3.36 ± 0.72 days, p>0.05). Histopathology 
examinations (Figure 4A, a5, a6, b5, b6, c5, c6) further 
verified MR imaging findings. As shown in Figure 4A, 
a5, there was only a thin layer of tumor tissues, within 
which was a large area of necrosis. Although once 
suffered seriously deliberate damage, the residual tumor 
still maintained the exuberant vitality, rendering apparent 
tumor recurrence around central necrosis (Figure 4A, 
b5) and circumjacent blood vessels (Figure 4A, b6). 
There was no obvious necrosis in the tumor of group C 
(Figure 4A, c5) and these tumor cells revealed remarkable 
malformation as well as mitosis (Figure 4A, c6).
Autoradiography
It was apparent that in the dead center of microwave 
ablation region, low uptake of 131I-Hyp appeared during 
the whole observation period according to autoradiography 
(Figure 5, A1, B1, C1) and macrography (Figure 5, A2, B2, 
C2) images. This might probably be due to that microwave 
energy destroyed the micro vessels that were the key 
transport corridors of drug delivery and more closed to the 
center, the vessels damaged more serious. High 131I-Hyp 
uptake appeared in tumor, normal liver and necrosis 
1 day post injection of 131I-Hyp (Figure 5, A1), which 
suggested that the injection drug had not been sufficiently 
metabolized. Over time, radioactivity uptake in normal 
liver gradually weakened and high radioactivity uptake 
mainly concentrated in the border of viable tumor and 
necrosis (Figure 5, B1) 4 days post injection of 131I-Hyp. 
Meanwhile, the radioactivity ratio of this border over 
normal liver was 16.7 judging by optiquant software. On 
day 9 (8 days post injection), high radioactivity uptake still 
occurred at the border of viable tumor and necrosis with 
a enhancing trend of radioactivity but further weakening 
Figure 2: Residual tumor induced by MWA with its MRI and histopathology verification. A. Schema chart of exocentric 
MWA. B&C. showed the tumor-bearing liver lobe before and after exocentric MWA. D. Contrast enhanced MRI before MWA showed 
a inhomogeneously elliptic enhancement on the edge of left liver lobe, with some hypointense signal in the center. E. Contrast enhanced 
MRI after MWA revealed a typical ring-enhancement at the same location, within which appeared extensive hypointense signal area. F. 
Gross photography of axial frozen section performed H&E staining corresponding to the same layer of Figure 2E. The collapse of the 
central area (N) and the adjacently dark blue area (T) represented necrosis and viable tumor respectively. G. This micrograph suggested 
the magnification field of the red rectangular frame delineated in Figure 2F, which showed both abnormal tumor cells and cracked necrosis 
incontrovertible (200 ×).
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in central necrosis and normal liver (Figure 5, C1). The 
radioactivity radio of this border over normal liver reached 
40.9. These results were basically identical with gamma 
counting (Figure 3C, 3D).
Fluorescence microscopy and histopathology
Corresponding fluorescence images further verified 
this dynamic trend. 1 day post injection of 131I-Hyp, 
fluorescence intensity mainly focused on necrosis and 
lesser distributed in normal liver and tumor (Figure 5, 
A4). With time passed by, the fluorescence intensity can 
persistently concentrated in necrosis with a strengthening 
trend while barely not in normal liver and tumor (Figure 
5, B4, C4).
DISCUSSION
In this study, we established orthotopic liver 
allograft sarcoma model on rat and induced extensive 
tumor necrosis with MWA. 131I-Hyp could bind to necrotic 
tumor after MWA and inhibit residual tumor recurrence. 
According to the present results, we concluded that 
therapeutic outcomes of local thermal ablation can be 
improved on rat orthotopic liver allograft sarcoma models 
by 131I-Hyp induced necrosis targeted radiotherapy.
To the best of our knowledge, ideal specific tumor 
targeting tends to increase drug efficacy in targeted 
region and is less likely to damage collateral organs [27, 
28]. Gamma counting results showed high non-targeted 
organs distributions of 131I-Hyp (lung, spleen, large 
intestine, bladder, etc.) at early time, and rapid clearances 
occurred within the half-life period of 131I (8.04 days). 
Eventually 131I-Hyp presented a persistent and increasing 
accumulation in necrotic tumor (Figure 3C, 3D), which 
guaranteed durable cross-fire ionizing radiation around 
the residual tumor. SPECT-CT images confirmed that 
prominent radioactive “hot spots” appeared at the position 
of the liver tumor. However, the signal was also very 
high in lung and intestinal canal (Figure 3A). This may 
attribute to the aggregation of hypericin which further 
activated immunizing phagocytosis conducted by organs 
Table 1: Post mortem gamma counting results of following samples on day 5 and day 9 (4 d and 8 d post injection 
of 131I-Hyp)
Organ
% injected dose/g
Day 5 Day 9
Blood 0.0505 ± 0.0158 0.0086 ± 0.0074
Thyroid 0.0566 ± 0.0425 0.0338 ± 0.0186
Lung 0.2609 ± 0.1175 0.0588 ± 0.0698
Heart 0.0709 ± 0.0158 0.0105 ± 0.0061
Spleen 0.0739 ± 0.0478 0.0275 ± 0.0166
Stomach 0.1009 ± 0.0280 0.0399 ± 0.0375
Pancreas 0.0938 ± 0.0695 0.0545 ± 0.0282
Small intestine 0.0588 ± 0.0432 0.0372 ± 0.0385
Large intestine 0.1774 ± 0.2453 0.0244 ± 0.0155
Kidney 0.0892 ± 0.0306 0.0149 ± 0.0095
Bladder 0.1372 ± 0.0285 0.0242 ± 0.0144
Brian 0.0017 ± 0.0017 0.0013 ± 0.0010
Skeleton 0.0420 ± 0.0216 0.0228 ± 0.0178
Normal liver 0.0596 ± 0.0112 0.0146 ± 0.0077
Viable tumor 0.2431 ± 0.1762 0.0247 ± 0.0195
Necrotic tumor 0.3476 ± 0.1669 0.9169 ± 1.1138 **
Muscle 0.0856 ± 0.0499 0.0982 ± 0.1015
The radioactivity was reported as a percentage of the injected dose per gram of tissues (% ID/g).
Numerical data were reported as the mean ± standard deviation.
** The injected dose per gram of necrotic tumor was significantly higher than that of other organs (p < 0.01).
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rich in mononuclear phagocyte system (MPS) cells such 
as lung and spleen. Besides, hypericin was excreted via 
the hepatobiliary pathway to the intestinal canal and 
further concentrated in the abdomen on account of severe 
abdominal distension [29, 30].
Over time, the radioactive “hot spots” persistently 
appeared in the liver tumor. In vitro radioautography 
and fluorescent microscopy confirmed that 131I-Hyp 
persistently deposited in the target tissue (necrotic tumor) 
and rapidly excreted from non-target tissues (normal 
liver and viable tumor) (Figure 5). However, thyroid 
and intestine also showed high signals (Figure 3B). The 
deiodination of 131I-Hyp in vivo and serious flatulence 
caused by operation related adynamic ileus which could 
be certified by corresponding coronal CT image (Figure 
3, A5, B5), may have accounted for this appearance. In 
addition, some excreta adhering on the fur of rat may also 
attribute to the high radioactivity in the abdominal cavity. 
Tumor inhibition was observed during the 8 day follow-
up and 131I-Hyp could persistently concentrate in necrotic 
areas induced by MWA, significantly prolong TDT 
and inhibited recurrence of residual tumors compared 
to the control group. This was verified by in vivo MRI 
and corresponding histopathology (Figure 4). In terms 
of valid radiation dose, 50 Gy was essential to achieve 
tumoricidal effect for most neoplasms to our knowledge 
[33]. Ni’s group [22] utilized 131I-Hyp (300 MBq/kg, i.v.) 
to treat R1-tumor bearing rats, estimated to correspond to 
a cumulative dose of about 5000 Gy over 8 days. In our 
study, 131I-Hyp was administered at 74 MBq/kg, which 
was according to previous reports [22, 33] estimated 
as approximately 1250 Gy during the same time. As a 
consequence, the theoretical tumor suppression could be 
achieved in our study.
Figure 3: In vivo SPECT-CT A, B. and post mortem γ counting C, D. for rats receiving i.v. injection 131I-Hyp at different 
time point. The planar axial scintigraphy (A1), CT (A2) and fusion images (A3) showed high radioactivity uptake in accurate location on 
day 3, while A4, A5 and A6 showed corresponding coronal planar expressions. B1-B6 showed analogous patterns for another rat on day 8. 
C&D represented the biodistribution of 131I-Hyp by mean of percentage of the injected dose per gram of tissues (% ID/g) on day 5 and day 
9 respectively. ** The % ID/g was significantly higher than that of other organs (p < 0.01).
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Some unanticipated events occurred during the 
study. Figure 6 depicted the persistence of “tumor-like” 
tissue around the probe track (yellow rectangle), which 
could hardly be distinguished from normal tumor tissue 
using conventional H&E staining. Previous studies have 
indicated similar phenomena (“ghost phenomena” or 
“thermal fixation”) with VX2 tumor bearing rabbits and 
RIF-1 tumor bearing mice who received radiofrequency 
ablation (RFA) [31, 32]. To distinguish ablated and 
unablated tumor and normal liver tissue, Ni’s group 
[32] used nicotinamide adenine dinucleotide (NAD) 
staining to confirm that this “tumor-like” tissue had no 
Figure 4: Representative in vivo MRI at different time points of each group and tumor growth trend. During the 8 days 
following up, tumor grew comparatively slow in group A (a1-a4). While tumor growth seemed standstill for group B before day 4, the 
eventual volume still became far larger than baseline (b1-b4). For group C, tumor just kept growing rapidly with a gradually enlarging 
elliptic enhancement, which probably meant vigorous proliferation for tumor cells. a5, b5, c5. The macroscopic photographs of each group 
harvested from corresponding rats further confirmed the information deriving from in vivo MRI. a6, b6, c6. These photomicrographs 
denoted magnifying fields of yellow rectangular frames delineated in a5, b5 and c5 (50 ×, 100 ×, 400 × respectively). T, tumor; N, necrosis; 
L, liver. B. Tumor growth curves showed tumors in group B and C grew faster than that of group A. C. Tumor doubling time of group A 
was significantly lower than that of group B and C (A vs. B, p < 0.01; A vs. C, p < 0.01). There was no significant difference between group 
B and C (p > 0.05). **p < 0.01, ns p > 0.05.
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Figure 5: Dynamic in vitro autoradiography, fluorescence microscopy and corresponding histopathology results. 
From the left to right column were orderly autoradiography (A1, B1, C1), macrography (A2, B2, C2), histopathology (A3, B3, C3) and 
fluorescence microscopy (A4, B4, C4) images, while from the top to bottom meant 1 day (A1, A2, A3, A4), 4 days (B1, B2, B3, B4) and 
8 days (C1, C2, C3, C4) post injection of 131I-Hyp respectively. A3, B3, C3 (50 ×) denoted magnifying fields of yellow rectangular frames 
delineated in A2, B2, C2 respectively. A4, B4, C4 (50 ×) shared the same microscopic fields with A3, B3, C3. L, T and N denoted liver, 
tumor and necrosis respectively.
Figure 6: Ghost phenomenon. A. Macrograph of H&E staining section containing necrosis, normal liver and viable tumor. B. Low-
magnification microscopic field (50 ×) of yellow rectangular frame delineated in A. C. High-magnification microscopic field (400 ×) of 
green rectangular frame delineated in A. D. High-magnification microscopic field (400 ×) of yellow rectangular frame delineated in B.
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activity and was likely dead. They speculated that rapid 
increases in temperature of RFA denatured enzymes while 
preserving in tissue architecture and cytological detail. 
Similar to RFA, MWA had the same capacity to produce 
instantaneous high temperature with a more moderate 
process, therefore, this was likely a so-called “ghost 
phenomenon” or “thermal fixation”, and this represents 
the first report of such in W256 tumor bearing rats after 
MWA.
Whether therapeutic radionuclide can be delivered 
into the tumor microenvironment and persist there 
without causing adverse events is a key consideration of 
treatment. Compared with 131I-chTNT, 131I-Hyp remained 
in target tissue at greater concentrations with a ratio of 
retention time for 3 weeks to 3 days [34], largely due 
to the relatively smaller molecular weight (<1 kDa) of 
hypericin compared to macromolecular weight (>30 kDa) 
of monoclonal antibodies [33]. Thus, 131I-Hyp can more 
easily penetrate the tumor tissue microenvironment for the 
subsequent cross-fire radiotherapy.
There were some limitations in our study. First, 
the dose chosen for 131I-Hyp was based on published 
literature without experimental certification. Next, we 
failed to perform histochemical staining to verify ghost 
phenomenon in the process. Finally, we did not monitor 
survival, toxicity, or treatment-related side effects. In 
addition, the present research failed to illuminate the 
detailed mechanism of hypericin about its favorable 
affinity to necrosis.
Conclusion
Our study did demonstrate that 131I-Hyp can 
persistently bind to necrotic tumor after MWA and further 
inhibit residual tumor recurrence on rat orthotopic liver 
allograft sarcoma models. MWA in combination with 
131I-Hyp may offer synergistic anticancer therapy for 
tumor treatment and further studies on necrotic affinity 
mechanism of hypericin are warranted.
MATERIALS AND METHODS
Animal model
All experiments were approved by institutional 
Animal Care and Use Committee of China Medical 
University. Male Sprague Dawley rats (250-300 g) were 
provided by the Institutional Laboratory Animal Center. 
Animals were divided into donor (N=5) and recipient 
animals (N=30). For the donor animals, Walker 256 
(W256) cells (2 × 106) were inoculated (percutaneously) 
in bilateral axilla every two weeks. Two weeks later, 
donor rats were anesthetized with 10% chloral hydrate 
(3 mL/kg, i.p.) and a standard laparotomy was performed 
to expose livers. Small tumor blocks (1 mm diameter) 
were harvested from donor rats. These tumor blocks were 
embedded in the left lobe of each liver of recipient rats 
that were anesthetized and laparotmized in the same way. 
Tumor embedding was accomplished using a handmade 
tumor conveyer. If necessary, a gelatin sponge was used 
for hemostasis. For all animals, layered sutures were used 
to close the abdominal cavity and recipient animal tumor 
blocks propagated until tumor diameters were 0.8 ± 0.2 
cm. This was monitored every 3 days by MRI.
Experimental design
Figure 1 depicts the experiment. Lugol’s solution 
(1.2 g/L drinking water) was given to animals 3 days 
Figure 1: Flow chart of the experimental procedures in rats with orthotopic liver W256 allograft. (MWA, microwave 
ablation; Hyp, hypericin; n, number).
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before treatment to prevent thyroid uptake dissociative 131I 
until the study end. Thirty rats orthotopic liver allograft 
tumors that were 0.8 ± 0.2 cm diameter were randomly 
divided into three groups: Group A (n = 10) received intra-
operative MWA and injection of 131I-Hyp (74 MBq/kg, 
i.v.) after 24 h; Group B (n = 10) received intra-operative 
MWA and vehicle; Group C (n = 10) were blank controls 
treated with sham ablation and they received surgical 
interventions but without microwave energy delivery, and 
then they received vehicle after 24 h.
As 131I-Hyp alone has been documented to have 
little tumoricidal activity [18, 22], we deliberately did not 
include a control group of 131I-Hyp treatment alone. Also, 
we minimized the radiation injury during all procedures. 
Tumor inhibitory effects among all groups were monitored 
in real time using in vivo MRI prior to (baseline) and 24 
h, 4 and 8 days after MWA application. Group A received 
in vivo SPECT-CT scans at days 3 and 8 to monitor 
distribution of radionuclides. To verify in vivo imaging 
findings postmortem, 3 rats from Group A were sacrificed 
at 24 h and 4 d and 8 d after 131I-Hyp treatment and then 
autoradiography, fluorescent microscopy, and gamma 
counting were performed. Rats of group B and C were 
histopathologically studied on day 9.
Microwave ablation protocol
Rats with tumor diameters of 0.8 ± 0.2 cm were 
identified as MWA candidates. MWA was performed 
using a 2450 Hz cool-shaft (KY-2000; Kangyou Medical 
Instruments, Nanjing, China), transmitting microwaves 
via a 14-gauge cool-circle microwave ablation therapeutic 
probe (KY-2450B; Kangyou Medical Instruments, 
Nanjing, China) with an anterior pole of 5 mm, featuring 
a continuous sinusoidal microwave form. After anesthesia 
and standard laparotomy, liver tumors were exposed. 
Figure 2A and 2B indicated probe visualization at the 
tumor edge for retaining viable tumor material. Once the 
probe reached the designated location, microwave energy 
was delivered (10 W) for 60 s, and this was determined 
to be appropriate for inducing necrosis according to in 
vitro experiments on excised rat livers. After MWA of the 
tumor, the probe was gently removed with ongoing MWA 
emission until the probe tip approached the liver surface. 
This was intended to prevent tumor metastasis along the 
needle tract as far as possible (Figure 2C). The same 
abdominal closure was used on all animals as previously 
described. To confirm residual tumors, contrast enhanced 
MRI was performed 24 h before and after (Figure 2D, 2E) 
MWA procedures.
Radiolabeling
Hypericin (purity 99%) was purchased from Purifa 
Co., Ltd, Chengdu, China. Sodium iodide (Na131I) with 
a specific activity of 740 MBq/mL (radionuclidic purity 
>99%) was purchased from HTA Co., Ltd, Beijing, China.
An Iodogen coating method was used to form 
131I-Hyp. Hypericin was first dissolved in DMSO (0.5 
mg/ml) and radio-iodination was triggered by adding 
the hypericin DMSO solution and Na131I solution onto 
an Iodogen-coated tube with (volume ratio hypericin/
Na131I, 4:1). The mixture was allowed to incubate for 30 
min at room temperature and the reaction was terminated 
by removal of the mixture. Radioactive labeling was 
confirmed using paper chromatography with filter paper 
(Whatman No. 1; GE healthcare, Piscataway, NJ) and 
0.01 N HCL as a stationary and mobile phase. At last, the 
mixture was diluted with polyethylene glycol (PEG) 400 
and propylene glycol (volume ratio, 1:1:1) and given to 
animals (74 MBq/kg i.v.) to study radiobiodistribution and 
tumor inhibitory effects.
In vitro stability studies
To determine the in vitro stability of 131I-Hyp, the 
mixture of 131I-Hyp and rat serum (volume ratio, 1:9) 
was incubated at 37°C for 72 h. Plasma proteins were 
precipitated by adding 300 μL of ethanol and removed 
by centrifugation (12000 rpm, 10 min). The stability was 
assayed by using reversed-phase high performance liquid 
chromatography (RP-HPLC).
Biodistribution studies
Rats (N = 3) from each time point (24 h, and 4 and 8 
d post-injection of 131I-Hyp) were euthanized as depicted in 
the Methods. Then, brains, thyroids, lungs, hearts, spleens, 
stomachs, pancreas, small and large intestines, kidneys, 
bladders, skeletons, livers, viable and necrotic tumors, 
and muscle were sampled, weighed, and radioactivity 
was measured in each using an automatic gamma counter 
(2470 WIZARD PerkinElmer, city, MA). After corrections 
for physical decay and background radiation, activity was 
expressed as a percent of the injected dose/g tissue (% 
ID/g), which represented biodistribution of 131I-Hyp.
SPECT-CT imaging
Group A received a SPECT-CT scan 2 and 7 days 
post-treatment of 131I-Hyp with a variable-angle dual 
detector SPECT with 16-slice CT (Symbia T; Siemens 
Medical Systems, Chicago, IL) unit. After anesthetization 
with chloral hydrate (0.3 g/kg, ip), rats were secured by 
the head on a platform in a supine position. SPECT-CT 
images were collected as follows: static image matrix 
size 128 × 128; acquisition count limit 50,000; SPECT 
tomographic image matrix 64 × 64; and continuous 
acquisition 15 s/frame × 24 frames.
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MR imaging
MRI was performed with a 1.5 T whole body MRI 
scanner (Echo speed; GE Co., New York, USA) with a 
rat coil (Chenguang Medical Technologies Co., Ltd, 
Shanghai, China). Rats were anesthetized using a small 
animal gas anesthesia machine (Matrix VMP; GENE&I, 
Beijing, China) with 2% isoflurane mixed with 20% 
oxygen/80% room air. Rats were then positioned supinely. 
Detailed scanning is described thusly:
T2 weighted image (T2WI): sequence pattern, 
fast spin-echo (FSE); repetition time (TR) / echo time 
(TE), 2920/88 msec; field of view (FOV), 100×100 mm; 
imaging acquisition matrix, 224×192; slice thickness, 2 
mm; gap, 0.1 mm; total acquisition time, 3 minutes and 
1 second.
T1 weighted image (T1WI): sequence pattern, spin-
echo (SE); TR/TE, 550/24 msec; FOV, 100×100 mm; 
imaging acquisition matrix, 224×192; slice thickness, 2 
mm; gap, 0.1 mm; flip angle, 80º; total acquisition time, 3 
minutes and 5 seconds.
Contrast enhanced T1WI (CE-T1WI): sequence 
pattern, spin-echo (SE); TR/TE, 550/60 msec; FOV, 
100×100 mm; imaging acquisition matrix, 224×192; 
slice thickness, 2 mm; gap, 0.1 mm; flip angle, 80º; Total 
acquisition time, 3 minutes and 31 seconds. CE-T1W 
images were acquired immediately after intravenous bolus 
of gadodiamide (GE Healthcare AS) at 0.2 mmol/kg [23].
Processing and analysis of MR images
All MRI data were sent to an external dedicated 
workstation (Advantage Workstation, ADW 4.5, GE 
Medical Systems, New York, USA) and analyzed by three 
specialized radiologists. Regions of interest (ROI) which 
were tumor mass areas on each tumor-containing slice 
were manually delineated using a drawing tool. Tumor 
volume (TV) was calculated as follows: TV = tumor area 
on each tumor containing slice x (slice thickness + gap). 
Tumor doubling time (TDT) was calculated by TDT = (T 
- T0) ×log2/(logV - logV0), where (T - T0) indicates the 
time interval between two measurements, V and V0 denote 
the tumor volume at the two points of measurement [24].
Autoradiography
Tumor-containing hepatic lobes of Group A rats 
were harvested as indicated and instantly frozen in OCT 
medium (Tissue-Tek; Sakura Finetek, Torrance, CA), and 
then serially sectioned (8- and 30 μm) using a cryotome 
(Shandon FSE, Thermo Fisher Scientific Co., Waltham, 
UK) and were thaw-mounted on glass slides. Then, 30-
μm frozen sections were exposed for 12 h on a high-
performance storage phosphor screen (Cyclone; Canberra-
Packard, Ontario, Canada) to obtain autoradiographs. All 
acquired images were analyzed with Optiquant software 
(Canberra-Packard, Ontario, Canada) and radioactivity 
ratios of necrotic to normal hepatic tissue were estimated 
by manually indicating (drawing) ROIs. These 30-μm 
frozen sections then were stained with hematoxylin & 
eosin (H&E) and compared with autoradiographs.
Fluorescence microscopy and histopathology
Next, 8-μm frozen sections were imaged 
under fluorescent microscopy with a digital camera 
(AxioCam HR, CarlZeiss, Germany) to observe 
hypericin fluorescence. After bright light and fluorescent 
microphotography, the 8-μm sections were stained with 
H&E and microphotography was again performed using 
the same fields of view as the previous fluorescent images. 
Group B and C rat tissues were treated the same to acquire 
microscopic images of tumor-containing liver lobes.
Statistical analysis
Statistical analysis was conducted by using 
Graphpad Prism 5.0 software. Numerical data are reported 
as the mean ± standard deviation. One - way ANOVA was 
recruited to test differences among groups. Unpaired two-
tailed Student t tests were performed for comparisons of 
two mean values. A P value of less than .05 was considered 
statistically significant.
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